CGRP Infusion Shows Efficacy in Cluster Headache Management
After success in migraine treatment, CGRP has now shown a positive effect on acute cluster headache in a randomized clinical trial.
FDA Accepts Sodium Oxybate Application for Children With Narcolepsy
The FDA has accepted a supplemental new drug application for sodium oxybate as a treatment for cataplexy and excessive daytime sleepiness in children with narcolepsy.
Can Neurologists Identify Patient Suicide Warnings?
Given that suicide is increasing as a public health concern, better identification of warning signs could assist in directing preventative strategies to the right people.
Positive Topline Results Announced for BAN2401 in Phase II Alzheimer Trial
The anti-amyloid protofibril antibody achieved statistical significance in its key efficacy endpoints after 18 months.
Sports and Headaches: A Risky Business Quiz
Which sports-related migraine is associated with longer recovery time, as well as cognitive, neurobehavioral, and somatic symptoms? Test your skills in this quiz.
Promising Cell Therapy Unavailable for ALS Under Right-to-Try
The autologous stem cell therapy is currently in a phase III trial.
Galcanezumab Shows Efficacy in Cluster Headache, Migraine
Phase III results have shown galcanezumab is efficacious for multiple headache conditions.
Eptinezumab Reduces Monthly Migraine Days Post-Third, Fourth Infusions
The anti-CGRP treatment continues reducing migraine days a year after patients received infusions.
Rimegepant Eases Pain, Resolves Symptoms for Acute Migraine
Rimegepant significantly reduced pain and the most bothersome symptom while showing an "excellent" safety profile for patients with acute migraine attacks.
Quarterly Infusions of Eptinezumab Highly Effective for Migraine Prevention in PROMISE 2
The intravenous quarterly CGRP inhibitor eptinezumab significantly reduced monthly migraine days compared with placebo for patients with chronic migraine.
Neurology Comic: Stress Test
We're trying to make our stress tests more realistic.
Riluzole Prolongs Late-Stage Survival in ALS
A retrospective analysis of a dose-ranging trial found that those who were administered 100-mg daily riluzole, in comparison with placebo, spend a longer period of time in stage 4 of ALS.
FDA Accepts APL-130277 Application for OFF Episodes in PD
The FDA had accepted a new drug application for APL-130277, a sublingual film version of apomorphine, as a treatment for OFF episodes in patients with Parkinson disease.
FDA Approves Cannabidiol for Lennox-Gastaut, Dravet Syndromes
The FDA has approved cannabidiol oral solution for the treatment of seizures associated with Lennox-Gastaut syndrome and Dravet syndrome for patients 2 years of age and older.
Gene Therapy Shows Robust Activity for Duchenne Muscular Dystrophy
A novel gene therapy has demonstrated impressive early results in a small sample of 3 children with Duchenne muscular dystrophy.
VY-AADC Gene Therapy Receives FDA RMAT Designation for Parkinson
Across 3 cohorts, the therapy showed improvements in on-time without troublesome dyskinesia, ranging from 2.1 hours to 3.5 hours.
Updated Clinical Guidelines on the Ketogenic Diet in Children with Epilepsy
Nearly a decade in the making, revised guidelines provide 8 key points for effective nonpharmacologic treatment of epilepsy in childhood.
California Startup Exploring Novel ALS Discovery Platform
A grant from the National Institute of Neurological Disorders and Stroke, which allows for concurrent phase I and II trial design review, will speed up the development of novel treatments for patients with ALS and FTD.
Ocrelizumab Delays Disability Progression in Primary Progressive Multiple Sclerosis
Those treated with ocrelizumab observed a 46% reduction in their risk of progressing to a wheelchair compared to those administered placebo treatments.
Lemborexant Shows Positive Results in Pair of Phase I Studies
The results of a pair of trials of lemborexant support phase III findings of the investigational sleep-wake regulator.
FDA Grants Priority Review to Perampanel for Pediatric Seizures
The FDA has granted a priority review designation to perampanel for 2 potential new indications for pediatric patients with seizures.
Mini Quiz: Treatment-Induced Neuropathy of Diabetes
What are the key symptoms of TIND, a rare condition that can occur after rapid normalization of blood glucose levels following prolonged periods of hyperglycemia?
Neurological Consult Using Audiovisual Tools
How effective is the telemedicine versus telephonic approach in acute care?
Antibody Testing in Patients With Neurological and Psychiatric Symptoms
New research may help doctors determine when (and when not) to test for antiglutamate decarboxylase antibodies in patients with neurological disorders and psychiatric symptoms.
FDA Approves EmboTrap II for Thrombectomy in Ischemic Strokes
The FDA has approved the EmboTrap II Revascularization Device for thrombectomy within 8 hours of the appearance of symptoms for patients with ischemic stroke.
FDA Grants Pitolisant Breakthrough, Fast Track Designations in Narcolepsy
The FDA has granted a Breakthrough Therapy and Fast Track Designation to pitolisant for cataplexy in patients with narcolepsy, as Harmony Biosciences prepares a new drug application for the drug.
Neuropsychiatric Problems Associated With Lupus
A new study has found that patients with neuropsychiatric systemic lupus erythematosus have 3 times increased risk of death, and this risk increases to over 7 times higher in patients with focal CNS symptoms.
Erenumab, First Novel CGRP Inhibitor, Gains FDA Approval for Migraine Prevention
The first-in-class anti-CGRP monoclonal antibody erenumab has gained FDA approval for the prevention of migraines.
Update on Myasthenia Gravis Treatment
New treatments for MG may have a more direct effect on the action of acetylcholine on the neuromuscular junction than steroids, IVIG, and plasmaphoresis.
FDA Approves Fingolimod as First Multiple Sclerosis Therapy for Children
The FDA has expanded the indication for fingolimod to include the treatment of children and adolescents age 10 years and older with relapsing multiple sclerosis.
